Related Experiment Video
Updated: Feb 14, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
Frameshift events predict anti-PD-1/L1 response in head and neck cancer
Glenn J Hanna1, Patrick Lizotte1,2, Megan Cavanaugh1,2
1Department of Medical Oncology, and.
Abstract:
Programmed cell death protein 1 (PD-1) inhibitors have efficacy in treating squamous cell carcinoma of the head and neck (SCCHN), but objective response rates are low. PD-1 ligand (PD-L1) expression alone is not considered a robust predictor of response and additional biomarkers are needed. This 3-year observational cohort followed 126 SCCHN patients treated with anti-PD-1/L1 therapy. Prior to treatment, 81 (64%) had targeted massively parallel tumor sequencing. Of these, 42 (52%) underwent fluorescence-activated cell sorting and PD-L1 immunohistochemistry for tumor immunoprofiling. Six (5%) complete responses (CRs) and 11 (9%) partial responses (PRs) were observed. Those treated with prior chemotherapy (98, 78%) versus only surgery and/or radiation had longer overall survival (OS) (10 vs. 3 months, P = 0.02). Smokers had a higher total mutational burden (TMB) (P = 0.01). Virus-positive patients had a lower TMB (P < 0.01) and improved OS (P = 0.02). Among virus-negative responders, NOTCH1 and SMARCA4 were more frequently mutated and frameshift events in tumor suppressor genes occurred more frequently (P = 0.03). Higher TMB and CD8+ T cell infiltrates predicted anti-PD-1/L1 benefit (P < 0.01, P < 0.01, respectively) among virus-negative tumors. TIM-3/LAG-3 coexpression with PD-1 was higher on T cells among nonresponders (P = 0.03 and 0.02, respectively). Somatic frameshift events in tumor suppressor genes and higher TMB among virus-negative SCCHN tumors predict anti-PD-1/L1 response.
Insights
Identifying biomarkers for anti-PD-1/L1 therapy in head and neck cancer is crucial. Higher tumor mutational burden and specific gene mutations in virus-negative tumors predict better response to immunotherapy.
Area of Science:
- Oncology
- Immunology
- Genetics
Background:
- Programmed cell death protein 1 (PD-1) inhibitors show promise for squamous cell carcinoma of the head and neck (SCCHN).
- Objective response rates are limited, and Programmed cell death ligand 1 (PD-L1) expression is not a definitive predictor of response.
- There is a need for novel biomarkers to guide anti-PD-1/L1 therapy selection in SCCHN.
Purpose of the Study:
- To identify predictive biomarkers for anti-PD-1/L1 therapy in SCCHN patients.
- To investigate the relationship between tumor mutational burden (TMB), viral status, gene mutations, and immune cell infiltrates with treatment response.
- To explore potential biomarkers beyond PD-L1 expression.
Main Methods:
- An observational cohort study of 126 SCCHN patients treated with anti-PD-1/L1 therapy.
- Tumor sequencing, fluorescence-activated cell sorting, and immunohistochemistry were performed for immunoprofiling.
- Analysis of overall survival (OS), TMB, gene mutations (NOTCH1, SMARCA4), and immune markers (CD8+, TIM-3, LAG-3).
Main Results:
- Low objective response rates (14%) were observed.
- Higher TMB and CD8+ T cell infiltrates predicted anti-PD-1/L1 benefit in virus-negative tumors (P < 0.01).
- Somatic frameshift events in tumor suppressor genes and mutations in NOTCH1/SMARCA4 were associated with response in virus-negative SCCHN (P = 0.03).
- TIM-3/LAG-3 coexpression was higher in non-responders.
Conclusions:
- Higher TMB and CD8+ T cell infiltrates are promising biomarkers for predicting anti-PD-1/L1 therapy response in virus-negative SCCHN.
- Somatic frameshift events in tumor suppressor genes may also predict response.
- Further research is warranted to validate these biomarkers for clinical application in SCCHN immunotherapy.
More Related Videos
07:43Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018
10:18Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
Related Concept Videos
Arteries of the Head and Neck
The internal carotid arteries supply blood to the anterior portion of the cerebrum. They enter the...
Veins of Head and Neck
On the other hand, the vertebral veins, unlike their arterial counterparts, are not primarily responsible for brain drainage. Instead, they drain the cervical vertebrae, spinal cord, and some small...
Predicting Products: SN1 vs. SN2
With increased substitution on the alkyl halide,...
Point and Frameshift Mutations
PD Controller: Design
Designing a continuous-data controller requires selecting and linking components like adders and integrators, which are fundamental in Proportional,...
Predicting Molecular Geometry